Insider Selling: Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Sells 20,000 Shares of Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon sold 20,000 shares of the stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $10.77, for a total value of $215,400.00. Following the sale, the director now directly owns 761,283 shares of the company’s stock, valued at $8,199,017.91. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Cyrus Harmon also recently made the following trade(s):

• On Monday, June 3rd, Cyrus Harmon sold 5,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $10.93, for a total value of $54,650.00.
• On Friday, May 31st, Cyrus Harmon sold 15,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $9.41, for a total value of $141,150.00.
• On Monday, May 6th, Cyrus Harmon sold 5,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $10.92, for a total value of $54,600.00.
• On Tuesday, April 30th, Cyrus Harmon sold 15,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $9.51, for a total value of $142,650.00.

Olema Pharmaceuticals Price Performance

NASDAQ OLMA opened at $10.67 on Thursday. Olema Pharmaceuticals, Inc. has a 12 month low of $7.78 and a 12 month high of $17.79. The stock has a 50 day moving average of $10.88 and a 200-day moving average of $11.99.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.03). As a group, equities analysts expect that Olema Pharmaceuticals, Inc. will post -2.3 earnings per share for the current year.

Institutional Investors Weigh In On Olema Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Public Employees Retirement System of Ohio acquired a new stake in Olema Pharmaceuticals during the 3rd quarter valued at $35,000. China Universal Asset Management Co. Ltd. acquired a new stake in Olema Pharmaceuticals during the 4th quarter valued at $89,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Olema Pharmaceuticals during the 4th quarter valued at $130,000. Entropy Technologies LP acquired a new stake in Olema Pharmaceuticals during the 1st quarter valued at $161,000. Finally, EntryPoint Capital LLC lifted its holdings in Olema Pharmaceuticals by 949.9% during the 1st quarter. EntryPoint Capital LLC now owns 14,530 shares of the company’s stock valued at $164,000 after purchasing an additional 13,146 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. The Goldman Sachs Group assumed coverage on Olema Pharmaceuticals in a research report on Tuesday, April 2nd. They set a “buy” rating and a $24.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Olema Pharmaceuticals in a research report on Tuesday, June 4th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $22.00.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.